secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRADIMED CORP (IRMD)
CIK:        0001325618
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001558370-23-017501
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iradimed reports record Q3 revenue $16.5M, raises FY GAAP EPS guidance to $1.34-$1.37
--------------------------------------------------------------------------------

- Q3 revenue $16.5M (+23% YoY); GAAP diluted EPS $0.40 vs $0.27 YoY; non-GAAP diluted EPS $0.43 vs $0.29 YoY.
- Operating income $5.9M, up 43% YoY; ninth consecutive quarterly revenue record led by monitoring business up 40% QoQ.
- Q4 2023 guidance: revenue $16.9M-$17.4M; GAAP EPS $0.35-$0.38; non-GAAP EPS $0.38-$0.41.
- Full-year 2023 guidance raised: revenue $65.0M-$65.5M; GAAP EPS $1.34-$1.37 (up from prior); non-GAAP EPS $1.48-$1.51.
- Cash flow from operations $3.5M in Q3 ($9.6M YTD) vs $2.4M ($7.0M YTD) YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/0001558370-23-017501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1325618/000155837023017501/irmd-20231103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer